Bi-specific aptamers are designed to specifically target two different antigens, one is multidrug-resistance-associated membrane protein 1 (MRP1), which is highly expressed in chemotherapy-resistant tumor cells, while another is CD28 on T lymphocytes, which functions to provide the co-stimulatory signals required for T cell activation and survival [123]. Here, CD28 is linked to neoplasm.